Fierce Pharma
AUGUST 14, 2024
With an FDA appro | The FDA has approved Gilead's primary biliary cholangitis treatment Livdelzi. The drug, which was acquired in a $4.3 billion buyout of CymaBay Therapeutics six months ago, is the first inflammatory treatment launched by Gilead.
MedCity News
AUGUST 14, 2024
Pharmacists and pharmacy technicians at a Walgreens store in Vancouver, Washington, have filed a petition to join the Pharmacy Guild. The workers argued that they are facing heavy workloads and inadequate staffing. The post First Walgreens Store Files to Unionize with the Pharmacy Guild appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
AUGUST 14, 2024
Johnson & Johnson and Roche are at the top of S&P Global’s pharmaceutical industry power ratings, which assess the strength of the world’s top 17 drugmakers. | Johnson & Johnson and Roche are at the top of S&P Global’s pharmaceutical industry power ratings, which assess the strength of the world’s top 17 drugmakers.
Pharma IQ
AUGUST 14, 2024
Discover how Otsuka and Oxford HIN are collaborating to evaluate and implement CARE for MDD, a digital therapeutic designed to treat major depressive disorder.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Fierce Pharma
AUGUST 14, 2024
Bluebird Bio is making progress on the launch of its three approved gene therapies but appears to be trailing Vertex in its competition to attract patients to their respective treatments for sickle | Bluebird Bio is making progress on the launch of its three approved gene therapies but appears to be trailing Vertex in competition to attract patients to their respective treatments for sickle cell disease.
MedCity News
AUGUST 14, 2024
Six months after Change Healthcare suffered its cyberattack, some health systems are still missing payments for patient encounters from February, according to a new report. It showed that small hospitals are still missing about 3-5% of expected net revenue for patient encounters from February. The post Health Systems Are Still Missing Payments Because of the Change Healthcare Cyberattack appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Commerce
AUGUST 14, 2024
In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, describes the outcome of the joint public meeting held by the Partnership for DSCSA Governance and the FDA.
MedCity News
AUGUST 14, 2024
Livdelzi is now FDA-approved for treating the rare liver disease primary biliary cholangitis. Gilead Sciences added the drug to its pipeline via the $4.3 billion acquisition of CymaBay Therapeutics earlier this year. The post FDA Awards Accelerated Approval to Gilead Sciences Drug for Rare Liver Disease appeared first on MedCity News.
pharmaphorum
AUGUST 14, 2024
Baxter International has agreed to sell its kidney treatment division to private equity firm Carlyle Group in a $3.8 billion cash deal, continuing its efforts to streamline its operations and reduce debt.
MedCity News
AUGUST 14, 2024
Next-generation robotic platforms have made a significant leap forward with real-time data analysis and intraoperative feedback, instilling a new confidence in surgical decisions while helping to minimize the potential for error during surgery. The post The Future of Robotic Surgery: Leading the Way with Digital Solutions appeared first on MedCity News.
Pharmaceutical Technology
AUGUST 14, 2024
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan), has received conditional approval in China for gastric cancer.
MedCity News
AUGUST 14, 2024
Current trends are driven by various strategic and financial considerations from both established pharmaceutical companies and development-stage biotech firms. Understanding the valuation and accounting implications of these transactions are crucial for stakeholders to navigate the complex landscape effectively. The post Valuation of Biotech Transactions: Trends, Drivers, and Implications appeared first on MedCity News.
pharmaphorum
AUGUST 14, 2024
The rapid spread of a new variant of mpox – previously known as monkeypox – has prompted the Africa Centers for Disease Control and Prevention (Africa CDC) to declare a public health emergency.
PharmaTimes
AUGUST 14, 2024
Heart failure with preserved ejection fraction makes up 50% of all UK heart failure cases
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
pharmaphorum
AUGUST 14, 2024
Firefly Neuroscience lists on Nasdaq via a $45m merger with IT firm WaveDancer, as it rolls out an AI-powered platform for managing brain function.
PharmaTech
AUGUST 14, 2024
AstraZeneca and Daiichi Sankyo first entered into an agreement to develop Enhertu in March 2019, and the antibody-drug conjugate has since been approved for various groups in more than 65 countries.
pharmaphorum
AUGUST 14, 2024
AstraZeneca has claimed the first regulatory approval for an immunotherapy/PARP inhibitor combination for endometrial cancer.
Pharmaceutical Commerce
AUGUST 14, 2024
The latest news for pharma industry insiders.
pharmaphorum
AUGUST 14, 2024
Otsuka and Click Therapeutics' first-in-class prescription digital therapeutic for depression launches in US through mobile app stores
PharmaVoice
AUGUST 14, 2024
The German biotech is leveraging its mRNA platforms to develop a new class of cancer treatments that are necessary to lift the company’s flagging sales.
PharmaTimes
AUGUST 14, 2024
The findings could improve cancer treatment and drug delivery to treat tumours
Clarify Health
AUGUST 14, 2024
Today’s h ealthcare providers face significant challenges that can impede their ability to deliver consistent, high-quality care. Fragmented and siloed care, inefficiencies and high operational costs, poor patient satisfaction, complicated chronic conditions, challenges to achieving value-based care metrics, a lack of insight into market insights, and inadequate patient follow-up care all present barriers to providing a holisti c patient journey and implementing strategic growth opportunities fo
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Evolve Your Success
AUGUST 14, 2024
Episode Description Unlock the secrets to harmonizing marketing and sales in the medical industry with Terrence Wiggins, the Global Marketing Director at Cook Medical. Discover how leveraging diverse marketing channels—from social media to promotional events—can catapult brand awareness and product success. Terrence demystifies the often-contentious relationship between sales and marketing, offering actionable tips for aligning these teams to achieve shared goals and maximize impact.
PM360
AUGUST 14, 2024
Designed To Support Patient Engagement And Improve Access To Medication Information Woburn, MA – August 8, 2024 – MedAdvisor Solutions, the global leader of pharmacy-driven patient engagement solutions, and Brand Engagement Network (BEN) , a provider of safe, personalized customer engagement AI, today announced that the companies’ revolutionary AI-driven medication advisor will be available for live demonstration at the 2024 National Association of Chain Drug Stores – Total Store Expo ( NAC
ALULA
AUGUST 14, 2024
When was the last time your team left a meeting feeling genuinely inspired? If you're struggling to remember, you're not alone. In a world of endless emails and back-to-back video calls, truly effective leadership communication has become a rare skill. It's not about how many words you say, but how deeply they resonate. It's about turning strategy into action, and hesitation into momentum.
PharmExec
AUGUST 14, 2024
Ken Keller, CEO of Daiichi Sankyo’s US business, reflects on the trials, triumphs, and lessons learned in steering the transformation of a legacy cardiovascular company into a global leader in oncology—advancing a vision for a reimagined future in cancer treatment.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
European Pharmaceutical Review
AUGUST 14, 2024
The US Food and Drug Administration (FDA) has approved the first monoclonal antibody that inhibits IL-31 cytokine signalling. The biologic is indicated for adults with prurigo nodularis, a chronic neuroimmune skin disease. Galderma’s Nemluvio ® (nemolizumab) is authorised as a pre-filled pen for administration via subcutaneous injection. FDA’s decision is based on positive results from two Phase III OLYMPIA clinical trials, OLYMPIA 1 and OLYMPIA 2.
PharmaTech
AUGUST 14, 2024
Yorvipath is a prodrug of parathyroid hormone (PTH) (1-34), designed to be administered once daily to provide continuous exposure to released PTH.
PharmExec
AUGUST 14, 2024
UGN-102 has the potential to be the first FDA-approved treatment for low-grade intermediate-risk non-muscle invasive bladder cancer, UroGen says.
Pharmaceutical Technology
AUGUST 14, 2024
In 2021, the Centers for Disease Control and Prevention estimated that 49 percent of the U.S. population had either pre- or type 2 diabetes.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
326 
Let's personalize your content